• THE RIGHT DIAGNOSTIC CAN SAVE YOUR LIFE

    We provide the most comprehensive test on the market

    ARE YOU A DOCTOR OF A PATIENT?

    We be happy to share our information with you

    WHY WE ARE DOING IT

    Only 1 out of 4 approved cancer treatments prolong life

  • WHAT WE DO

    We are sequencing RNA to identify the best drug for the patient and the best patient for the drug

    Only 1 out of 4 cancer treatments prolong life

     

    From a genetic perspective, every cancer is unique. Yet the treatment most patients are offered is a standard treatment based on tissue of origin and stage. 

     

    Sequencing provides a paradigm shift

     

    Sequencing has enabled a paradigm shift away from looking at colored cells in a microscope to define the cancer by its genetic drivers. The sequence data enabling the doctor to diagnose aggressive cancers early AND identify more effective treatments for later stage cancers with ONE comprehensive test.

     

    Cancer is no longer mainly defined by tissue of origin

     

     

     

    In many cases the same genetic alteration can be driving breast cancer in one patient, and lung cancer in another, opening up for many more treatment options.

     

     

    Often the test can identify a less toxic and more effective treatment

     

     

     

    Genetic testing using sequencing, opens up for treating with new types of drugs that target these genetic changes.  Often the test can identify a less toxic and more effective targeted treatment with less side effects.

     

    How we do it: OneRNA

    OneRNA assist doctors select the best drug for their patient, and Pharma companies select the best patient for their drug
     

     

    OneRNA(TM) is a novel sample prep method that uniquely extracts RNA from the cells in a manner that makes it easy to later identify and quantify the RNAs using sequencing. Once the sample has been prepared, it is sequenced on an Illumina NextGen system. The analysis of the data is performed using a HIPAA-compliant cloud-based solution developed in collaboration with IBM. This cloud solution generates a clinically actionable report for each tumor based on its gene expression profile.

     

    Are you a doctor or a patient?

    Finding the right drug for your patient Click here to learn more 

     

    Our OneRNA report can identify actionable alterations and link them to approved drugs and drugs in clinical development. We partner with doctors to accelerate the delivery of more effective care in oncology. 

     

    Are you developing new drugs ?

    Finding the right patient for your drug click here to learn more 

     

     

     

    OneRNA™ can assist you in selecting the right patients for your clinical trial. Reducing the number of different test to ONE, without compromising the number of markers you want to include. In fact you can have it all +20,000 RNA’s in ONE assay. Furthermore  adding a new marker is a simple update to our cloud-based software which we can do retrospectively. As such, OneRNA™is uniquely able to keep pace with rapidly evolving clinical research and cancer drug development. Finally we can help you focus on the right indication, expand your label on existing drugs, and create responder algorithms rather than relying on one marker as a companion diagnostic.

     

  • WHO WE ARE

    Gitte Pedersen

    Gitte Pedersen, CEO is a former executive at NovoZymes, the world’s largest enzyme manufacturer. She has advised the Danish Government and early stage biotech companies regarding their corporate development in the US

     

    Follow at DNABARCODE

    Morten Pedersen

    Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very strong innovation track record with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies
     

    Jesper Zeuthen

    Chief Medical Officer

    Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.

    Tanya Kanigan

    Chief Operating Officer

    Tanya Kanigan, COO has a post-doctoral degree from MIT and developed the OpenArray, which was then spun out into BioTrove and sold to Life Technology.

    Morten Middelfart

    Morten Middelfart, CIO holds two Ph.D.'s; one in data mining and machine learning, and one in business management. He has seven U.S. patents and 25 worldwide patents in his field and +20 years of analyzing Big Data.

  • Buy OneRNA(TM)

    Send us your samples or your RNA-seq data and we will send you an actionable report back

  • WHO'S TALKING ABOUT US

    We have been featured in GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Impact Investors such as Investor Circle, the largest impact investment angel groups in the world and a family office; Centurion Holding in New York.

     

    We are a Springboard alum company and among the 500 women owned technology companies they have supported

     

    Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Tech Challenge and invited to dinner with Branson on Necker’s Island, selected into the top 10 diagnostic companies at the Molecular Tri-Conference and then finalish in Top 100 Red Herring

  • Articles, Grants and Investors

    Grant 

    Genome Danmark

    Article 2011

    Interview 2014

    Feature Article 2014

    Accelerator

    Impact Investor

    Investor

    Impact Investor

    #2 at WFN

    Top 5 Mol Tri Conf.

    Top 10 XTC

    Top 100 Red Herring

    Horizon2020 grant

    Eurostars Grant

    Collaborator

    Winner of Owlers 2016 HOT in New York Award!

  • PRESIDENT OBAMA'S MOONSHOT PROGRAM

    Lead by Vice President Joe Biden - interview from Davos

     

    US Vice-President Joe Biden convenes international leaders in cancer research, cancer treatment and data science to discuss potential opportunities to advance the pace of progress in the fight against cancer.

    Speakers: Paula T. Hammond, Jennifer Doudna, Sylvia Mathews Burwell, Francis S. Collins, Joseph R. Biden Jr, Elizabeth Blackburn, Bill McDermott, Delos M. (Toby) Cosgrove, José Baselga, Charles Sawyers, David B. AgusTopics: Health, Fourth Industrial Revolution

     

  • WANT TO LEARN MORE ?

    We help doctors select the best drug for their patient, and pharma companies select the best patient for their drug

     

    DISCLAIMER

    The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.

  • TALK BACK

    Follow us on twitter 

  • YOU + SOCIAL MEDIA

    = SOCIAL IMPACT

    You're awesome. Let's talk.

    Twitter

     

    @DNABARCODE

     

    Sign up for news

     

    Youtube

     

    Linkedin

     

    +genomicexpression

     

    Telehone

    (646) 847-9290

     

    Invest

     

  • SHARING OUR OPPINIONS

    Welcome to the blog - feel free to share !

    All Posts
    ×